Table of Contents
Introduction and Abbreviations
-
- Introduction
- Definition
- Abbreviations and terms
- Abbreviations
- Terms
Executive Summary
-
- Age, ethnicity, and lifestyle combine with self-care and switches
- Chewable tablets, flavoring, and combo products help grow market
- Antacids dominate segments
- Six manufacturers dominate
- TV, print begin to share with Web advertising
- The consumer
- Aging and ethnic populations, switches, retail environment impact the future
- Market forecast
Market Drivers
-
- Incidence of gastrointestinal ailments increases
-
- Figure 1: U.S. population projections and number of GI ailment sufferers, by age, 2001-11
- Aging population equals windfall of GI industry
-
- Figure 2: Incidence of gastrointestinal ailments, by type of ailment, by age, 2005
- Diet and stress contribute to incidence
-
- Figure 3: Attitudes towards diet, September 2003-05
- Prescription switches to OTC
- Direct-to-consumer advertising boosts awareness
- Self-diagnosis and self-care continue momentum
- Insurance co-pay hikes
- Hispanic: A new generation of GI sufferers
-
- Figure 4: U.S. Hispanic population projections and number of GI ailment sufferers, by age, 2001-11
Market Size and Trends
-
- Market size
-
- Figure 5: Total U.S. FDM retail sales of gastrointestinal remedies, at current and constant prices, 2001-06
-
- Figure 6: Graph: Total U.S. FDM retail sales of gastrointestinal remedies, at current and constant prices,
- Market trends
-
- Figure 7: New gastrointestinal remedy product launches by product type, 2001-06
- Figure 8: Number of new gastrointestinal remedy products by price, 2001-06
Market Segmentation
-
- Overview
-
- Figure 9: FDM sales of gastrointestinal remedies, segmented by type, 2004 and 2006
- Figure 10: Graph: FDM sales of gastrointestinal remedies, segmented by type, 2004 and 2006
- Antacids
-
- Figure 11: FDM sales of antacids, at current and constant prices, 2001-06
- Laxatives
-
- Figure 12: FDM sales of laxatives, at current and constant prices, 2001-06
- Stomach remedies
-
- Figure 13: FDM sales of stomach remedies, at current and constant prices, 2001-06
- Anti-diarrheals
-
- Figure 14: FDM sales of anti-diarrheals, at current and constant prices, 2001-06
Supply Structure
-
- Companies and brands
-
- Figure 15: Manufacturer FDM sales of gastrointestinal remedies in the U.S., 2004 and 2006
- Antacids
-
- Figure 16: Manufacturer brand FDM sales of antacids in the U.S., 2004 and 2006
- Laxatives
-
- Figure 17: Manufacturer brand FDM sales of laxatives in the U.S., 2004 and 2006
- Stomach remedies
-
- Figure 18: Manufacturer brand FDM sales of stomach remedies in the U.S., 2004 and 2006
- Anti-diarrheals
-
- Figure 19: Manufacturer brand FDM sales of anti-diarrheals in the U.S., 2004 and 2006
- Company profiles
- Procter & Gamble
- Johnson & Johnson
- GlaxoSmithKline
- Novartis Consumer Health
- Pfizer, Inc.
- Other companies
Advertising and Promotion
-
- Introduction
-
- Figure 20: Estimated online streaming media expenditures, 2004-10
- Procter & Gamble
-
- Figure 21: Pepto Bismol ad featuring young basketball players, 2006
- GlaxoSmithKline
-
- Figure 22: Tums ad featuring roadside diners, 2006
- Johnson & Johnson-Merck
-
- Figure 23: Pepcid AC ad featuring “Jim” the adventurous eater, 2006
- Novartis
-
- Figure 24: Maalox ad feauturing, 2006
- Pfizer
-
- Figure 25: Rolaids ad featuring deflating tires, balloons, 2006
- McNeil
Retail Distribution
-
- Introduction
-
- Figure 26: U.S. retail FDM sales of gastrointestinal remedies, by channel, 2004 and 2006
- Drug stores
-
- Figure 27: U.S. mass merchandiser and club store sales of GI remedies, at current and constant prices,
- Mass merchandisers and clubs
-
- Figure 28: U.S. mass merchandiser sales of gastrointestinal remedies, at current and constant prices,
- Supermarkets
-
- Figure 29: U.S. supermarket sales of gastrointestinal remedies, at current and constant prices,
The Consumer
-
- Introduction
- Summary
- Incidence and severity of gastrointestinal ailments
-
- Figure 30: Incidence of GI ailments, by age, January-September 2005
-
- Figure 31: Severity of GI ailments, by age, January-September 2005
- Prescription vs. OTC
-
- Figure 32: Use of prescription vs. OTC product to treat GI ailment, by age, January-September 2005
- Types/kinds of OTC remedies preferred
-
- Figure 33: Types/kinds of OTC GI remedies preferred, January-September 2005
- Brands preferred
-
- Figure 34: Heartburn/indigestion aid brands preferred, January-September 2005
- Frequency of use of heartburn/indigestion aids
-
- Figure 35: Frequency of use of heartburn/indigestion aids, by age, January-September 2005
- Use of laxatives and types preferred
-
- Figure 36: Use of laxatives and types preferred, by age, January-September 2005
- Laxative brands preferred
-
- Figure 37: Laxative brands preferred, January-September 2005
- Frequency of laxative use
-
- Figure 38: Frequency of use of laxatives, by age, January-September 2005
- Attitudes towards GI ailments and remedies
-
- Figure 39: Attitudes towards GI ailments, by age, August 2006
-
- Figure 40: Alka-Seltzer ad featuring elderly consumers, 2006
-
- Figure 41: Attitudes towards GI remedies, by age, August 2006
-
- Figure 42: Self or doctor diagnosis of GI ailments, by problem, by age, August 2006
-
- Figure 43: Effectiveness of OTC GI Remedies, by problem, by age, August 2006
- Cohort analysis
- Incidence of GI ailments among cohorts
-
- Figure 44: Incidence of GI ailments, by cohort, January-September 2005
- Use of heartburn/indigestion aids and laxatives among cohorts
-
- Figure 45: Use of heartburn/indigestion aids and laxatives, by cohort, January-September 2005
- Race/ethnicity analysis
- Incidence of GI ailments among ethnicities
-
- Figure 46: Incidence of GI ailments, by race/ethnicity, January-September 2005
- Use of heartburn/indigestion aids and laxatives among ethnicities
-
- Figure 47: Use of heartburn/indigestion aids and laxatives, by race/ethnicity, January-September 2005
- Attitudes towards GI ailments and remedies among ethnicities
-
- Figure 48: Attitudes towards GI ailments, by race/ethnicity, August 2006
-
- Figure 49: Attitudes towards GI remedies, by race/ethnicity, August 2006
Future and Forecast
-
- Future trends
- Aging population continues to grow
-
- Figure 50: Total U.S. population, by age, 2001-11
- Prescription switches forecast to increase
- Hispanics represent growing opportunity
-
- Figure 51: U.S. Hispanic population, 2001, 2006, & 2011
- Prilosec protects its role in the market
- Retail pharmacy expands its healthcare role
- Market forecast
- Gastrointestinal remedies
-
- Figure 52: Forecast of total U.S. FDM sales of gastrointestinal remedies, at current and constant
- Figure 53: Graph: Forecast of total U.S. FDM sales of gastrointestinal remedies, at current and constant prices, 2006-11
- Antacids
-
- Figure 54: Forecast of U.S. FDM sales of antacids, at current and constant prices, 2006-11
- Laxatives
-
- Figure 55: Forecast of U.S. FDM sales of laxatives, at current and constant prices, 2006-11
- Stomach remedies
-
- Figure 56: Forecast of U.S. FDM sales of stomach remedies, at current and constant prices, 2006-11
- Anti-diarrheals
-
- Figure 57: Forecast of U.S. FDM sales of anti-diarrheals, at current and constant prices, 2006-11
- Forecast factors
Appendix: Trade Associations
Appendix: New Product Developments
-
- New product briefs
- McKesson: Sunmark Woman's Laxative Tablets
- Procter & Gamble: Cinnamon Fiber Wafers
- Johnson & Johnson: Mylanta Ultimate Strength Antacid
- Pfizer: Rolaids Plus Antacid & Antigas Gas Relief
- GlaxoSmithKline: Gaviscon Extra Strength Antacid Extension
- Albertson’s: Equaline Milk of Magnesia
Back to top